Palmitoyl Tetrapeptide-7
Rigin
Palmitoyl Tetrapeptide-7 (Rigin) is a healing & recovery research compound. Topical anti-inflammaging peptide — suppresses IL-6/IL-8 and boosts collagen to reduce photoaging and chronic skin inflammation.
Palmitoyl Tetrapeptide-7 quick facts
| Reported research dose | Topical, as directed |
| Route | Topical |
| Frequency | 1-2x Daily (topical) |
| Half-life | N/A (topical) |
| Forms | Topical |
| Evidence level | Cosmetic/topical |
Calms inflamm-aging in skin — pairs with Matrixyl (often sold together as Matrixyl 3000).
How Palmitoyl Tetrapeptide-7 works
Topical anti-inflammaging peptide — suppresses IL-6/IL-8 and boosts collagen to reduce photoaging and chronic skin inflammation.
Proposed benefits
Anti-inflammatory anti-aging skin support (cosmetic).
Where to get Palmitoyl Tetrapeptide-7
See vetted vendors for Palmitoyl Tetrapeptide-7 →The evidence for Palmitoyl Tetrapeptide-7
Graded by what exists behind each claim.
✅ Clinically validated
- Studied mostly in combination as Matrixyl 3000 (with palmitoyl tripeptide-1), where controlled work reports reduced wrinkle depth and improved skin density.
📊 Correlative data
- Very wide cosmetic use. Almost never used alone, which makes attributing the reported effect to it specifically impossible.
🧪 Theoretical / extrapolated
- Proposed to reduce production of interleukin-6, an inflammatory cytokine that drives glycation and matrix degradation in ageing skin.
- It is an anti-inflammatory rather than a collagen stimulant, which is precisely why it is paired with Pal-GHK: one reduces the damage, the other drives the repair. That pairing is mechanistically coherent rather than marketing.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Palmitoyl Tetrapeptide-7 actually does
The Cosmetic Ingredient Review defines this ingredient as the reaction product of palmitic acid with a four-residue peptide containing arginine, glutamine, glycine and proline CIR Expert Panel (Cosmetic Ingredient Review) 2012; the trade material is Gly-Gln-Pro-Arg. Computed from that sequence the free tetrapeptide is 456.51 Da with an isoelectric point of 10.55, and the palmitoylated molecule is 694.92 Da — heavier than every other palmitoylated peptide on this site except the collagen-fragment pentapeptide.
Here is the structural fact that separates this molecule from every one of its neighbors, and it is not in any product description. Palmitoylation caps the N-terminal amine. That leaves this peptide with exactly two ionizable groups: the guanidinium of arginine and the C-terminal carboxylate. They cancel. Run it through this site’s own chemistry module with the N-terminus acylated and the net charge is +0.01 at skin-surface pH 5.5 and effectively 0.00 at blood pH, with an isoelectric point of 8.05. Every other palmitoylated peptide in this family stays cationic after acylation — the lysine-rich ones sit near +1.00 at both pH values, the histidine ones near +0.92 at the skin surface. This one is a neutral zwitterion on the skin.
That matters more than the extra mass does. The intercellular route through stratum corneum is a lipid route, and a permanent positive charge is what pins a peptide to the anionic surfaces of keratin, sulfated glycosaminoglycans and the corneocyte envelope. A charge-balanced molecule is not held that way. So the prediction that falls out of the chemistry is counter-intuitive: this heavier peptide should move through skin more readily than its lighter, more cationic partners, and the fact that it is most used in eye-area products — where the stratum corneum is the thinnest on the body — puts it in the one place where a molecule this size has a chance. Eye-area use is the dominant category for it in the regulatory use survey CIR Expert Panel (Cosmetic Ingredient Review) 2012. Nobody has tested the prediction.
The proline is the other structural feature worth naming. A proline in position 3 locks the backbone into a turn, so this is the only conformationally constrained peptide in the group; the others are floppy chains. Proline also changes what can digest it — the bond on the far side of a proline resists ordinary aminopeptidases and needs a prolyl-specific enzyme — which is a structural reason to expect this peptide to outlast the others in tissue, independent of the palmitoyl group.
And now the claim. This ingredient is sold as an anti-inflammatory that suppresses interleukin-6, and it is usually paired with a palmitoylated collagen-fragment peptide on the argument that one calms and the other builds. Search the indexed literature for the interleukin-6 experiment and what you find is a study of Gly-His-Lys and Gly-Gly-His, and their copper complexes, lowering TNF-alpha-dependent IL-6 secretion in normal human dermal fibroblasts Gruchlik 2012. That is the other peptide in the pair. The published anti-IL-6 evidence in dermal fibroblasts belongs to the partner molecule, and the anti-IL-6 marketing belongs to this one. That is not a small mix-up: it is the whole rationale for the combination, and it points at the wrong half of it.
Cell, rodent, human — and where it stops
Cells: nothing indexed for this peptide. Gly-Gln-Pro-Arg appears in the biomedical literature as an entry in lists — named among anti-wrinkle peptides whose skin permeability is the field’s unaddressed problem Mortazavi 2022, and recorded as a constituent of marketed facial cosmetics Resende 2021. There is no indexed primary paper reporting a dose-response for it on fibroblasts, keratinocytes or any other cell, and no paper identifying a receptor for it. The supplier describes the sequence as an immunoglobulin-derived fragment; no indexed primary source establishes that origin or any receptor, and this page will not repeat it as though one did.
Rodents: nothing. No animal study of palmitoyl tetrapeptide-7 has been published.
Humans: only inside blends. Where it appears in a controlled cosmetic study it appears alongside a palmitoylated collagen-fragment peptide, and the result is attributed to the pair. A two-ingredient study cannot apportion an effect between two ingredients — that is not a criticism of the studies, it is what a two-ingredient design can and cannot do — and the reviews of this literature make the same structural point about topical peptides generally Gorouhi 2009. The nearest thing to a mechanistic anchor for the pair’s anti-inflammatory claim is a fibroblast IL-6 experiment run on the other component Gruchlik 2012.
The obstacle, and on this page it is the smallest in the cohort. 694.92 Da is well over the 500 Da rule for stratum corneum Bos 2000, and that is the standing objection. Three things push the other way, and together they make this the most likely of the group to actually arrive. First, charge: the acylated molecule is effectively neutral at skin pH, so it is not electrostatically pinned to the corneocyte surface the way its cationic relatives are. Second, site: the eye area is its dominant use category CIR Expert Panel (Cosmetic Ingredient Review) 2012, and eyelid skin carries the thinnest stratum corneum on the body. Third, in the one permeation study that exists in this family, the palmitoylated peptide was not simply stranded in the dead layer: 2.8 ± 0.5 µg/cm² was recovered from the viable epidermis against 4.2 ± 0.7 held in the stratum corneum, two-thirds as much in living tissue as in dead Choi 2014.
The arithmetic, and it is modest. An eye cream applied at 2 mg/cm² over roughly 25 cm² of periorbital skin delivers 50 mg of product; at a formulation level of 0.005% that is 2.5 µg of peptide per application, or about 3.6 nmol. Spread through the 25 cm² by 0.5 mm of viable tissue underneath — 1.25 mL — complete delivery would give roughly 2.9 µM, and a 5% delivery fraction gives about 150 nM. That is a real concentration in cell-biology terms, which is precisely why the missing piece here is not delivery but the absence of any cell experiment to compare it against. There is no published concentration at which this peptide does anything, so there is nothing to measure the 150 nM against. That is the gap on this page, and it is a different gap from the one on every other peptide card.
Palmitoyl Tetrapeptide-7 pharmacokinetics — how much of it actually gets in
What degrades it, and why this one is the odd case. Skin peptidases attack from the ends. The palmitoyl amide blocks aminopeptidase access at the N-terminus — measurably, in this family Choi 2014 — and the proline at position 3 blocks the common cleavages from the other direction, because bonds adjacent to proline require prolyl-specific enzymes rather than the general peptidases. A capped N-terminus and an internal proline is a protease-resistant design, whether or not anybody intended it. No half-life has been measured for it in skin or plasma in any species.
The barrier. 694.92 Da against the 500 Da rule Bos 2000, offset by a computed net charge of about zero at skin-surface pH, which is the property that governs whether a molecule is held at the surface or free to partition. No permeation study of this peptide exists in any skin model, so the comparison has to be borrowed from the palmitoyl-pentapeptide data in this cohort Choi 2014, where nothing crossed full-thickness skin into the receptor fluid but micrograms per square centimetre were recovered from the layers themselves.
Exposure, bounded. 2.5 µg per application to the eye area at 0.005%; twice daily for 12 weeks is roughly 0.4 mg in total. If the same product is used on the whole face, multiply by about sixteen for area. Those are the numbers any claim about this ingredient has to be consistent with.
Systemic exposure is not the question here. A charge-balanced 695 Da lipopeptide applied in microgram amounts, against plasma peptidases that clear small peptides in minutes, gives no meaningful circulating concentration, and no blood marker on this site has a route to move. The route is topical, the compartment is skin, and the only pharmacokinetics that matter are the ones inside it.
What would have to be true, and how you would know it was not
What to watch. Redness and periorbital appearance, measured rather than felt: a fixed-lighting, fixed-distance photograph of the eye area at week 0, 6 and 12, and if any instrument is available, an erythema index or a colourimeter reading from a marked spot. The claim is anti-inflammatory, so the read-out has to be an inflammation read-out, not a wrinkle one.
How long before it means anything. Six weeks for a redness change, twelve for anything structural. A cytokine-suppression mechanism should show up sooner than a collagen mechanism, which is itself a testable difference between this peptide and its usual partner.
What will fool you. The pairing. This ingredient is almost never sold alone, and its partner has a published fibroblast IL-6 result while this one has none Gruchlik 2012 — so the combination product is credited to the component with no data. The second trap is the eye cream itself: occlusion and hydration around the eye change the appearance of fine lines within days, and every impression formed in week one is that.
Prediction 1, the attribution test, and it cuts against this ingredient. Put the two components of the usual pair on separate halves of a face at their normal concentrations for 12 weeks. On the published evidence the prediction is that the other peptide produces at least as much of the anti-redness effect as this one, because the anti-IL-6 evidence in human dermal fibroblasts belongs to it Gruchlik 2012. If this one wins, that is a genuinely new result and the first direct evidence the ingredient has.
Prediction 2, from the charge chemistry, and it is the one this page is here to make. In a side-by-side Franz-cell permeation run, this 694.92 Da peptide should deliver more into the receptor compartment than the 578.79 Da cationic tripeptide it is normally sold with, despite being 116 Da heavier — because it is charge-neutral at the pH of the experiment and the lighter one is not. That is a prediction the 500 Dalton rule alone gets backwards Bos 2000, it takes one experiment, and nobody has run it.
Prediction 3, the irritation cross-test. If the anti-IL-6 claim is true at achievable concentrations, then co-formulating this peptide with a retinoid should reduce retinoid-induced erythema measurably at week 4 against the retinoid alone. That is a split-face study with a colourimeter, it has an obvious commercial motive, and it has not been published — which is itself informative.
What nobody has tested yet
1. There is no published dose-response for this peptide on any cell. Not one. The first experiment anybody should run is the simplest one in this file: normal human dermal fibroblasts, TNF-alpha stimulation, interleukin-6 by ELISA, this peptide across five concentrations, with Gly-His-Lys as the positive control because that is the arm with published data Gruchlik 2012. Until that exists, the central claim made for the ingredient has never been tested directly.
2. Nobody has verified the origin claim. The sequence is described commercially as an immunoglobulin-derived fragment. A database search against human protein sequences, published, would take an hour and would either give the ingredient a genuine matrikine pedigree or remove one of its selling points.
3. The charge prediction has never been measured. Computed net charge near zero at skin pH is a strong reason to expect better permeation than its cationic relatives, and permeation is the acknowledged blind spot of the whole category Mortazavi 2022. A single comparative Franz-cell study across the four palmitoylated peptides in this Vault, at equal molarity in one vehicle, would settle the structure-permeation question for all of them at once.
4. Nobody has looked for it in skin after use. The analytical chemistry for finding a cosmetic peptide in tissue and in creams is established — it has been done for other cosmetic peptides in commercial products Kluczyk 2021 — so the obstacle is not method, it is that no one has bothered.
5. The eyelid question. This ingredient is used mostly on the thinnest skin on the body CIR Expert Panel (Cosmetic Ingredient Review) 2012, and every permeation estimate for it borrows from studies on cheek, forearm or mouse skin. Nobody has measured peptide delivery across eyelid skin specifically, which is where the whole category’s best-case delivery argument would either be confirmed or quietly abandoned Pickart 2018.
Palmitoyl Tetrapeptide-7 — its own safety story, not its class's
The class block above is written for injectable repair peptides. This ingredient’s own risk profile is narrow, and the honest version of it is mostly about where it is applied and what is claimed.
Eye-area use is the specific risk, and it is not toxicological. This is the peptide in this Vault most likely to be applied within millimetres of the eye CIR Expert Panel (Cosmetic Ingredient Review) 2012. The relevant hazards there are mechanical and formulary rather than peptidergic: surfactant-like amphiphiles sting on contact with conjunctiva, and periorbital skin is the site where contact dermatitis to any leave-on ingredient shows up first and most visibly. Nothing about the molecule makes this worse than another eye-cream ingredient; nothing about it makes it safer.
The interaction question this card owns. Unlike the copper peptides in this Vault, there is no metal here, so no ascorbate-driven redox chemistry and no reason to separate it from a vitamin C serum. The interaction that is real is with retinoids, and it runs in the compound’s favor rather than against it: if the anti-IL-6 claim holds, this is the ingredient you would want beside a retinoid, and the reason to be careful is simply that two leave-on actives on eyelid skin produce one irritation and you will not know which caused it. There is no published interaction study for it with anything.
The claim that deserves scepticism rather than a warning. Suppressing interleukin-6 in skin is presented as unambiguously good. IL-6 is also part of normal wound repair and of the antimicrobial response, and a genuinely effective topical cytokine suppressor applied twice daily for years would be a longer conversation than a cosmetic one. The reason that conversation has not been necessary is that no experiment has ever shown this peptide suppressing IL-6 at any concentration Gruchlik 2012. If the ingredient worked as advertised, the safety question would be larger than the one currently asked.
Tolerability, and what it does and does not prove. Palmitoyl tetrapeptide-7 has been in wide leave-on use for two decades, including eye-area products, and it appears in surveys of marketed formulas without irritation flags Resende 2021. As with the other members of this family, that is reassurance about contact tolerance and evidence of nothing else — and on this card the absence of biological signal is unusually complete, because the compound also has no self-assembly, receptor or cell data of its own to point at Castelletto 2013.
Sources read for this page
- CIR Expert Panel (Cosmetic Ingredient Review). Safety Assessment of Palmitoyl Oligopeptides as Used in Cosmetics (scientific literature review). Cosmetic Ingredient Review 2012
- Gruchlik A, Jurzak M, Chodurek E, Dzierzewicz Z. Effect of Gly-Gly-His, Gly-His-Lys and their copper complexes on TNF-alpha-dependent IL-6 secretion in normal human dermal fibroblasts. Acta Pol Pharm 2012 · PMID 23285694
- Mortazavi SM, Moghimi HR. Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. Int J Cosmet Sci 2022 · PMID 35302659
- Resende DISP, Ferreira MS, Sousa-Lobo JM, Sousa E, Almeida IF. Usage of Synthetic Peptides in Cosmetics for Sensitive Skin. Pharmaceuticals (Basel) 2021 · PMID 34451799
- Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000 · PMID 10839713
- Choi YL, Park EK, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol Ther (Seoul) 2014 · PMID 25143811
- Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci 2009 · PMID 19570099
- Castelletto V, Hamley IW, Perez J, Abezgauz L, Danino D. Self-assembly of palmitoyl lipopeptides used in skin care products. Langmuir 2013 · PMID 23822110
- Kluczyk A, Ludwiczak J, Modzel M, Kuczer M, Cebrat M, Biernat M, Bartosz-Bechowski H. Argireline: Needle-Free Botox as Analytical Challenge. Chem Biodivers 2021 · PMID 33482052
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci 2018 · PMID 29986520
Palmitoyl Tetrapeptide-7 — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Active or recently treated malignancy — the angiogenesis reasoning.
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Palmitoyl Tetrapeptide-7 — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
Applied topically, this has no systemic exposure worth speaking of — so there is nothing to interact with anything you take, and no blood marker it could move. That is the honest answer rather than an empty section. The real interactions for a topical are layering ones: what you put on before and after it, and at what pH.
- How to work up to it, and when not to
- When to take it, and why that window
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Palmitoyl Tetrapeptide-7 in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Palmitoyl Tetrapeptide-7
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation — the thing you're claiming to reduce |
| Complete Blood Count (CBC) with Differential | Infection, anemia and platelet count before anything injectable |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Vitamin D (25-Hydroxy) | Low D slows soft-tissue and bone healing measurably |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
Palmitoyl Tetrapeptide-7 — frequently asked questions
What is Palmitoyl Tetrapeptide-7?
Palmitoyl Tetrapeptide-7 (Rigin) is a healing & recovery research compound. Topical anti-inflammaging peptide — suppresses IL-6/IL-8 and boosts collagen to reduce photoaging and chronic skin inflammation.
Is the full Palmitoyl Tetrapeptide-7 protocol on this page?
The reported research dose is on this page, along with how Palmitoyl Tetrapeptide-7 works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Palmitoyl Tetrapeptide-7?
Palmitoyl Tetrapeptide-7 has an approximate half-life of N/A (topical), which is part of what determines how often it's dosed.
What's the evidence behind Palmitoyl Tetrapeptide-7?
Current evidence level: Cosmetic/topical. Palmitoyl Tetrapeptide-7 is offered for research purposes only and is not an approved medicine.
What Palmitoyl Tetrapeptide-7 is used for
Palmitoyl Tetrapeptide-7 appears under 1 goal in the goal router.
Related Healing & Recovery compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.